A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

NCT04296890 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Epithelial Ovarian Cancer
Peritoneal Cancer
Fallopian Tube Cancer

Interventions

DRUG: Mirvetuximab Soravtansine

Sponsor

ImmunoGen, Inc.